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Objectives: The aim of this study was to evaluate the resistance profiles of Aggregatibacter
(Actinobacillus) actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia/
Prevotella nigrescens and to detect possible changes in antibiotic resistance over the time period of
1991–2005.
Methods: A. actinomycetemcomitans (125 strains), P. gingivalis (152 strains) and P. intermedia/
P. nigrescens (326 strains) isolated during the years 1991–2005 were tested for their susceptibility to
amoxicillin/clavulanic acid, clindamycin, metronidazole, phenoxymethylpenicillin and tetracycline
using the Etest.
Results: No antibiotic resistance was detected in P. gingivalis, whereas a few isolates of P. intermedia
were not susceptible to clindamycin (0.9%), phenoxymethylpenicillin (13.5%) or tetracycline (12.6%).
Amoxicillin/clavulanic acid, tetracycline and metronidazole were the most effective antibiotics against
A. actinomycetemcomitans with 0%, 0.8% and 20.8% non-susceptible isolates, respectively. However,
88% of the A. actinomycetemcomitans isolates were non-susceptible to phenoxymethylpenicillin and
88% to clindamycin. When strains isolated in the years 1991–94 were compared with those isolated in
the years 2001–04, there was no statistically significant difference in the percentage of A. actinomyce-
temcomitans strains non-susceptible to clindamycin, metronidazole or phenoxymethylpenicillin, or
in the percentage of P. intermedia strains non-susceptible to phenoxymethylpenicillin or tetracycline
(P > 0.4 each).
Conclusions: Increasing antibiotic resistances in periodontopathogenic bacteria are not yet a problem
in the Northern part of Switzerland.
Keywords: Etest, MIC, Aggregatibacter (Actinobacillus) actinomycetemcomitans, Porphyromonas gingivalis,
Prevotella intermedia
Introduction
The oral cavity is colonized by a diverse microflora. Several
bacterial species have been implicated as causative agents of
various oral diseases. Porphyromonas gingivalis and Prevotella
intermedia/Prevotella nigrescens are black-pigmented, strictly
anaerobic Gram-negative rods. P. gingivalis is frequently associ-
ated with aggressive periodontitis, whereas P. intermedia has
also been implicated as a causative agent of periodontitis.1
These species are also among the predominant bacteria isolated
from odontogenic abscesses.2 Aggregatibacter (Actinobacillus)
actinomycetemcomitans is a Gram-negative, capnophilic cocco-
bacillus mainly associated with localized aggressive periodonti-
tis.3 However, it has also been isolated from other oral sites than
the periodontal pocket,4 as well as from non-oral infections such
as abscesses and endocarditis.5
In the therapy of orofacial odontogenic abscesses, which are
mostly polymicrobial infections, antibiotics are often given in
addition to surgical drainage.6 In the case of periodontal dis-
eases, most patients respond well to a therapy consisting of
mechanical and surgical debridement. However, antimicrobial
agents are used as adjuncts after conventional treatment failures
and in aggressive periodontitis.7
As for numerous other microorganisms, increasing antibiotic
resistance among oral bacteria may also be a potential major
public health problem; however, only one study comparing resist-
ances in oral bacteria has been published so far, comparing iso-
lates collected from 1980–85 to isolates from 1991–95.8
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Additionally, the prevalence of resistance varies between
geographic locations.9 Therefore, the aim of this study was
to evaluate the resistance profile of oral isolates of A. actinomy-
cetemcomitans, P. gingivalis and P. intermedia from the
North-western part of Switzerland and to detect possible changes
in antibiotic resistance over the time period of 1991–2005.
Materials and methods
Isolation of bacteria
One hundred and twenty-five strains of A. actinomycetemcomitans,
152 strains of P. gingivalis and 326 strains of P. intermedia/
P. nigrescens have been isolated from various intraoral sites
(Table 1) during the years 1991–2005 and stored at 2708C
(Microbank, Chemie Brunschwig, Basel, Switzerland).
P. gingivalis and P. intermedia/P. nigrescens were isolated on
human blood agar plates [Columbia Agar Base (BBL Becton–
Dickinson, Allschwil, Switzerland) supplemented with 5 mg/L
haemin, 1 mg/L menadione and 50 mL/L human blood]. For the
isolation of A. actinomycetemcomitans, trypticase-soy-bacitracin-
vancomycin-agar plates were used.10 Identification of the pigmented
colonies and of A. actinomycetemcomitans was based on Gram’s
stain and cell morphology, aerotolerance, production of catalase and
on biochemical reactions (rapid ID 32 A; bioMe´rieux, Meyrin,
Switzerland) and/or with a selected set of biochemical reactions
(Rosco, Mecolab, Ho¨lstein, Switzerland). The black-pigmented
Prevotella-species P. intermedia and P. nigrescens were not differ-
entiated and are referred to as P. intermedia.
One isolate per patient was selected for the antimicrobial
susceptibility testing.
Antimicrobial susceptibility testing
The susceptibilities of the selected bacterial species were determined
by the Etest method. The antibiotics used were: amoxicillin/clavula-
nic acid (2/1), clindamycin, metronidazole, phenoxymethylpenicillin
and tetracycline (DMD, Arlesheim, Switzerland), the most com-
monly used antibiotics in dentistry in Switzerland.11 Inocula of
the test strains were prepared in 0.9% NaCl, adjusted to a turbidity
equivalent to that of at least a 0.5 McFarland standard and inoculated
on Brucella plates supplemented with 50 mL/L human blood and
1 mg/L menadione. One Etest strip of the respective antibiotic was
placed in the middle of each plate and the plates were then incubated
under appropriate conditions (air þ 10% CO2 for A. actinomycetem-
comitans and 10% CO2, 10% H2, 80% N2 for anaerobes and for A.
actinomycetemcomitans in the case of testing metronidazole, respect-
ively) for at least 48 h. The MICs were determined according to the
manufacturer’s instructions.
Bacteroides fragilis ATCC 25285 was included in each run as
quality control.
The breakpoints for susceptibility of anaerobes to the antibiotics
were applied for P. gingivalis and P. intermedia as recommended by
the Clinical and Laboratory Standards Institute.12 In the case of
A. actinomycetemcomitans, the interpretive criteria for the HACEK
group (i.e. the aphrophilus cluster of the genus Haemophilus,
A. actinomycetemcomitans, Cardiobacterium species, Eikenella cor-
rodens and Klingella species) were applied for amoxicillin/clavula-
nic acid and penicillin, whereas for metronidazole those for
anaerobes were used. As no interpretive criteria exist for clindamy-
cin and tetracycline, the interpretive criteria for anaerobes were
applied.12,13 Concentrations of antimicrobial agents achievable in
the gingival crevicular fluid mostly correlate well with the interpre-
tive categories by the Clinical and Laboratory Standards Institute.14
Data analysis
The numbers of susceptible and non-susceptible isolates during the
years 1991–94 and 2001–04 were compared by the two-tailed
Fisher’s exact test using the software Analyse-it for Microsoft Excel
(Analyse-it for Microsoft Excel, Leeds, UK, Version 1.72).
Results
Table 2 shows the in vitro susceptibility of the three oral patho-
gens A. actinomycetemcomitans (n ¼ 125), P. gingivalis (n ¼
152) and P. intermedia (n ¼ 326) to the five antibiotics tested.
All antibiotics were highly active against P. gingivalis.
Amoxicillin/clavulanic acid, clindamycin and metronidazole
were very effective against P. intermedia, while 13% of the
isolates were not susceptible to either phenoxymethylpenicillin
or tetracycline. A. actinomycetemcomitans showed a high level
of resistance to phenoxymethylpenicillin and clindamycin. All
isolates were susceptible to amoxicillin/clavulanic acid and
80% to metronidazole. One A. actinomycetemcomitans isolate
had an intermediate resistance to tetracycline, whereas all other
isolates were susceptible to this antibiotic.
The numbers of susceptible and non-susceptible (resistant
plus intermediate) isolates during the years 1991–94 versus
2001–04 were compared in order to detect a potential increase
in antibiotic resistance over time. No statistically significant
difference was detected in the susceptibility of A. actinomyce-
temcomitans or P. intermedia (Table 3).
Discussion
The black-pigmented anaerobe P. gingivalis was highly sus-
ceptible to the tested antibiotics amoxicillin/clavulanic acid,
Table 1. Oral sources of the bacterial isolates tested
Periodontal diseases Abscesses Other oral diseases Diagnosis not specifieda
A. actinomycetemcomitans 118 2 1 4
P. gingivalis 128 4 5 15
P. intermedia/P. nigrescens 256 19 27 24
Total 502 25 33 43
aFor some isolates, especially for strains isolated in the early 90s, it was not possible to retrospectively obtain the exact clinical diagnosis.
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clindamycin, metronidazole, phenoxymethylpenicillin and tetra-
cycline. This is in accordance with other studies which show
that this bacterium is highly susceptible to various anti-
biotics.2,8,15–18 Other investigators, however, detected resistances
in subgingival P. gingivalis isolates and isolates from odonto-
genic abscesses.9,19 In this context, it is important to note
that P. gingivalis has recently been shown to be capable of
conjugal transfer of chromosomal and plasmid DNA which
would provide an effective way to also transfer resistance
determinants.20
The other black-pigmented anaerobe, P. intermedia, was also
very susceptible to the antibiotics amoxicillin/clavulanic acid,
clindamycin and metronidazole, whereas 13% of the isolates
were non-susceptible to phenoxymethylpenicillin or tetracycline.
Amoxicillin/clavulanic acid, metronidazole and clindamycin are
generally regarded as highly effective against Prevotella species,
including P. intermedia, with the majority of oral origin suscep-
tible to these antibiotics.9,15–17,21–23 Tetracycline was less active
in this study. Tetracyclines are frequently used in the treatment
of periodontal diseases, also in the form of local delivery
devices.24 The proportion of P. intermedia isolates resistant to
tetracycline and its derivatives, primarily doxycycline and mino-
cycline, differed in other studies,9,17,21,22 which was mainly
attributed to the varying degree of their use in different
countries.9 Prevotella species are known to produce
b-lactamases.2,25,26 This may in part explain the resistance of the
Table 2. In vitro susceptibility of the oral bacterial isolates
Microorganism and antibiotic
MIC (mg/L)a
Percentage susceptiblerange 50% 90%
A. actinomycetemcomitans
amoxicillin/clavulanic acid ,0.016 to 3 1 2 100
clindamycin ,0.016 to .256 12 32 12b
metronidazole ,0.016 to .256 2 128 79.2
phenoxymethylpenicillin ,0.016 to 64 4 16 12
tetracycline ,0.016 to 12 0.38 0.75 99.2b
P. gingivalis
amoxicillin/clavulanic acid ,0.016 to 0.064 ,0.016 ,0.016 100
clindamycin ,0.016 to 0.125 ,0.016 ,0.016 100
metronidazole ,0.016 to 0.016 ,0.016 ,0.016 100
phenoxymethylpenicillin ,0.016 to 0.047 ,0.016 ,0.016 100
tetracycline ,0.016 to 2 0.023 0.19 100
P. intermedia/P. nigrescens
amoxicillin/clavulanic acid ,0.016 to 0.75 0.016 0.047 100
clindamycin ,0.016 to .256 ,0.016 ,0.016 99.1
metronidazole ,0.016 to 0.5 0.047 0.125 100
phenoxymethylpenicillin ,0.016 to 64 0.016 2 86.5
tetracycline ,0.016 to 32 0.064 6 87.4
a50% and 90% indicate the MIC values at which 50% and 90% of isolates were inhibited, respectively.
bNo available interpretive criteria. The interpretive criteria for anaerobic bacteria were applied.
Table 3. Total number of isolates during the years 1991–94 and 2001–04, the number of non-susceptible isolates and the corresponding
P value
Microorganism and antibiotic
Number of isolates 1991–94 Number of isolates 2001–04
Ptotal non-susceptible Total non-susceptible
A. actinomycetemcomitans 77 21
clindamycin 67 19 1
metronidazole 17 3 0.65
phenoxymethylpenicillin 66 20 0.44
P. intermedia/P. nigrescens 143 116
phenoxymethylpenicillin 20 17 1
tetracycline 18 15 1
Susceptibility of periodontopathogenic bacteria
1089
P. intermedia isolates in this study to penicillin, as all isolates
were susceptible to amoxicillin/clavulanic acid. With 13% non-
susceptible isolates, we detected a relatively low resistance to
penicillin compared with findings from other parts of the
world.9,17,21–23
A. actinomycetemcomitans was the least susceptible species,
with amoxicillin/clavulanic acid and tetracycline being the most
effective antibiotics. The high susceptibility of A. actinomycetem-
comitans to these two antibiotics is corroborated by other
studies.9,17,27 One notable exception, however, was that 100% of
subgingival A. actinomycetemcomitans isolated from Spanish
patients grew on tetracycline-containing agar plates versus 0%
isolated from Dutch patients.9 Approximately 20% of the
A. actinomycetemcomitans isolates from Basel were not suscep-
tible to metronidazole. Data on the susceptibility of A. actinomy-
cetemcomitans to this antibiotic vary.9,17,19,27,28 A.
actinomycetemcomitans was incubated differently in these
studies, either anaerobically, as in our study, or under capnophi-
lic/microaerophilic conditions. Metronidazole, however, is a
prodrug that has to be activated by a redox-reaction. This
reduction takes place most effectively under anaerobic con-
ditions.29 Although the metabolism of A. actinomycetemcomitans
under in vivo conditions is not known, metronidazole plus amoxi-
cillin show clinical success in patients with periodontal diseases
and are therefore recommended to eradicate this bacterium.30 The
least effective antibiotics were phenoxymethylpenicillin and clin-
damycin. Although penicillins are commonly used against micro-
organisms of the HACEK group,13 only 12% of the oral isolates
were susceptible to this antibiotic. This is in line with the study of
Eick et al.19 where only 6.2% of the A. actinomycetemcomitans
isolates were susceptible to penicillin. Higher susceptibility rates
were reported by Madinier et al.27 with 60% and by van
Winkelhoff et al.9 with 57.1% of the Dutch and 100% of the
Spanish isolates to be susceptible to penicillin. There are also
diverging results concerning the effectiveness of clindamycin
against A. actinomycetemcomitans.9,19,31 van Winkelhoff et al.9
found no A. actinomycetemcomitans isolates from The
Netherlands or from Spain growing on clindamycin-containing
agar plates. On the other hand, Miyake et al.31 and Eick et al.19
found this bacterium to be very resistant against clindamycin.
At many sites in the oral cavity, oral bacteria are organized
as a complex biofilm. Models of oral multispecies biofilms exist
and the effects of antimicrobial substances were studied.24,32,33
Most, but not all, species of subgingival bacteria were consider-
ably more resistant in biofilms than in planktonic cultures.24,33
MIC values presented in this study may also differ for A. actino-
mycetemcomitans, P. intermedia and P. gingivalis strains
growing in biofilms. However, bacteria in the subgingival
plaque can grow in different forms, either on the tooth surface
as a biofilm or more loosely organized in the non-adherent
plaque and antibiotic resistances may differ between these two
locations. Furthermore, A. actinomycetemcomitans and P. gingi-
valis are able to adhere and invade oral epithelial cells and can
even grow intracellularly.34 The efficacy of antibiotics with well
known intracellular activities was tested against these bacteria
within epithelial cells. It could be shown that the elimination of
intracellular bacteria by systemic antibiotics alone is proble-
matic.35 All these factors illustrate why the clinical success in
the management of periodontal diseases remains dependent on
mechanical treatment.7
The emergence of resistant pathogens is not only of concern
in medicine, but also in dentistry as it may be one reason for
treatment failure. Oral bacteria could also play an important part
in the spread of resistance genes. Viridans streptococci, which
are part of the normal flora, may act as a reservoir of antibiotic
resistance genes which subsequently may be transferred to
pathogens such as Streptococcus pneumoniae and Streptococcus
pyogenes.36 Genetic exchange between Treponema denticola
and Streptococcus gordonii has been demonstrated in biofilms in
vitro.37 Streptococci and other oral bacteria may transfer resist-
ance genes to intestinal bacteria.38
No increase in the prevalence of non-susceptible strains
could be detected in this study when P. intermedia or A. actino-
mycetemcomitans strains isolated during the years 1991–94
were compared with those isolated during 2001–04. This is in
contrast to Walker,8 the only study so far in which data of resist-
ances in oral bacteria were compared over time. Walker com-
pared 900 periodontal strains collected from 1980–85 to
300 periodontal strains from 1991–95, and reported significant
increases (P, 0.05) in the percentage of strains resistant to
tetracycline, doxycycline and amoxicillin. Furthermore, he could
detect a trend towards an increase in resistance to penicillin, but
there was no significant change in resistance to either erythromy-
cin or clindamycin. In the same study, Walker8 compared
several earlier studies and concluded that antibiotic resistances
to tetracyclines and penicillins have increased in the periodontal
flora.
Results of the two studies are difficult to compare as Walker8
analysed various oral bacterial species; we concentrated on the
three oral pathogens A. actinomycetemcomitans, P. intermedia
and P. gingivalis only. The two black-pigmented bacteria were
also tested by Walker in 1996. P. gingivalis was susceptible to
all seven antibiotics tested, including tetracycline, penicillin-G
and clindamycin, while the percentage of P. intermedia isolates
susceptible to these three antibiotics was in the same range as in
this study. A. actinomycetemcomitans was not analysed.8 In
addition to different methods and breakpoints, it is conceivable
that there can be an increase in antibiotic resistance for the total
oral flora, but not for individual species such as P. gingivalis,
P. intermedia and A. actinomycetemcomitans. It should be noted
that more than 500 bacterial species or phylotypes inhabit the
oral cavity.39 Therefore, to fully evaluate an increase in antibiotic
resistance, commensals but also other periodontopathogenic
species such as Tannerella forsythia, Fusobacterium nucleatum,
Campylobacter rectus and T. denticola need to be tested as well.
The level of resistance varies between countries, which can
be attributed to the different use of antibiotics.9 Among
European countries, Switzerland is the country with the lowest
antibiotic consumption per capita,40 which may in part explain
why antibiotic resistance did not increase among isolates from
the Basel area. Nevertheless, given the increase in antibiotic
resistances seen for other pathogens, a prudent use of antibiotics
in the management of periodontal diseases is still advisable.
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